Emilia
Balboa Beltrán
Publicacións nas que colabora con Emilia Balboa Beltrán (11)
2018
-
Clinical application of pharmacogenetics markers in colorectal cancer therapy
Clinical application of pharmacogenetics markers in colorectal cancer therapy
2015
-
Delimiting allelic imbalance of TYMS by allele-specific analysis
Medicine (United States), Vol. 94, Núm. 27, pp. e1091
-
Long Survival and Severe Toxicity under 5-Fluorouracil-Based Therapy in a Patient with Colorectal Cancer Who Harbors a Germline Codon-Stop Mutation in TYMS
Mayo Clinic Proceedings, Vol. 90, Núm. 9, pp. 1298-1303
2014
-
A novel stop mutation in the vascular endothelial growth factor-C gene (VEGFC) results in Milroy-like disease
Journal of Medical Genetics, Vol. 51, Núm. 7, pp. 475-478
-
The Complexity of Colorectal Cancer Biology — Putting Bricks on the Path to Personalized Medicine
Colorectal Cancer - Surgery, Diagnostics and Treatment
2012
-
The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens
Cancer Chemotherapy and Pharmacology, Vol. 69, Núm. 6, pp. 1591-1599
-
X-ray cross-complementing group 1 and thymidylate synthase polymorphisms might predict response to chemoradiotherapy in rectal cancer patients
International Journal of Radiation Oncology Biology Physics, Vol. 82, Núm. 1, pp. 138-144
2011
-
Evolutionary analyses of entire genomes do not support the association of mtdna mutations with ras/mapk pathway syndromes
PLoS ONE, Vol. 6, Núm. 4
-
Use of a comprehensive panel of biomarkers to predict response to a fluorouracil-oxaliplatin regimen in patients with metastatic colorectal cancer
Pharmacogenomics, Vol. 12, Núm. 3, pp. 433-442
2010
-
Pharmacogenetic analysis in neoadjuvant chemoradiation for rectal cancer: High incidence of somatic mutations and their relation with response
Pharmacogenomics, Vol. 11, Núm. 6, pp. 747-761
2009
-
Analysis of pharmacogenetic biomarkers in rectal patients trated with chemoradiotherapy
Journal of Clinical Oncology